Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 539-547 , August 2009

Malignancy in systemic lupus erythematosus: what have we learned?

  • Sasha Bernatsky, MD, PhD (Assistant Professor)

      Affiliations

    • Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 514 934 1934x44710; Fax: +1 514 934 8293.
    • ,
  • Rosalind Ramsey-Goldman, MD, Dr PH (Solovy Arthritis Research Society Professor, Research Professor of Medicine)

      Affiliations

    • Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    • ,
  • Ann E. Clarke, MD, MSc (Associate Professor)

      Affiliations

    • Divisions of Clinical Immunology/Allergy and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada

References 

  1. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;165(20):2337–2344
  2. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996 Sep;32A(10):1753–1757
  3. Bjornadal L, Lofstrom B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66–71
  4. Bernatsky S, Boivin J, Lawrence J, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52(5):1481–1490
  5. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum. 2002 Jul;46(7):1830–1839
  6. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control. 2008 Oct;19(8):887–894
  7. Feinstein AR, Walter SD, Horwitz RI. An analysis of Berkson's bias in case-control studies. J Chronic Dis. 1986;39(7):495–504
  8. Bernatsky S, Boivin JF, Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005 Oct 15;53(5):781–784
  9. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998;46(5):217–222
  10. Bernatsky S, Boivin J, Manzi S, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557
  11. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006 Jan 4;98(1):51–60
  12. Lofstrom B, Backlin C, Sundstrom C, et al. Lymphoma subtypes and prognosis in patients with systemic lupus erythematosus. [abstract] Arthritis Rheum. 2005;9:S1960
  13. Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005 Oct;64(10):1507–1509
  14. Lofstrom B, Backlin C, Sundstrom C, et al. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007 Dec;66(12):1627–1632
  15. Kojima M, Itoh H, Shimizu K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol. 2006 Jan;14(1):43–48
  16. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006 Sep 20;98(18):1321–1330
  17. Bernatsky S, Ramsey-Goldman R, Isenberg D, et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford). 2007 May;46(5):830–832
  18. Landgren O, Linet MS, McMaster ML, et al. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer. 2006 Jun 15;118(12):3095–3098
  19. Landgren O, Zhang Y, Zahm SH, et al. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2342–2347
  20. Ali YM, Urowitz MB, Ibanez D, Gladman DD. Monoclonal gammopathy in systemic lupus erythematosus. Lupus. 2007;16(6):426–429
  21. Ekstrom SK, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008 Apr 15;111(8):4029–4038
  22. Bin J, Bernatsky S, Gordon C, et al. Lung cancer in systemic lupus erythematosus. Lung Cancer. 2007 Jun;56(3):303–306
  23. Adzic TN, Pesut DP, Nagorni-Obradovic LM, et al. Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. Respir Med. 2008 Apr;102(4):620–624
  24. Bernatsky S, Clarke A, Ramsey-Goldman R, et al. Breast cancer stage at time of detection in women with systemic lupus erythematosus. Lupus. 2004;13(6):469–472
  25. Bernatsky SR, Cooper GS, Mill C, et al. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol. 2006 Jan;33(1):45–49
  26. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum. 2007 May;56(5):1446–1453
  27. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006 Jan;54(1):38–46
  28. Turner-Warwick M, Lebowitz M, Burrows B, et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980;35:496
  29. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;161(1):5–8
  30. King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol. 2007 Sep;26(9):1491–1494
  31. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma–meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford). 2007 Apr;46(4):690–694
  32. Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007 Jun;66(6):815–817
  33. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241–249
  34. Bernatsky S, Boivin JF, Joseph L, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case–cohort study. Ann Rheum Dis. 2008 Jan;67(1):74–79
  35. Bernatsky S, Clarke A, Suissa S. Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis. Ann Rheum Dis. 2008 Feb;67(2):277–278
  36. Evans SJ, Watson DK, O'Sullivan M. Reversible Hodgkin's lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE. Rheumatology (Oxford). 2008 Jul;47(7):1103–1104
  37. Soderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006 Nov;42(17):3028–3033
  38. Mellemkjaer L, Pfeiffer RM, Engels EA, et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. 2008 Mar;58(3):657–666
  39. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006 Jan;7(1):27–38
  40. Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum Pathol. 1986 Mar;17(3):254–263
  41. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun. 2001 Dec;2(8):442–450
  42. Ramos-Casals M, la CL, de VS, et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum. 2007 Feb 15;57(1):161–170
  43. Brady G, Macarthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J. 2008 Jul;84(993):372–377
  44. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115
  45. Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004 Sep;31(9):1763–1767
  46. Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004 Nov;50(11):3619–3625
  47. Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007 May 15;57(4):619–625
  48. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003 Aug;102(2):417–427
  49. Febronio MV, Pereira RM, Bonfa E, et al. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus. 2007;16(6):430–435

PII: S1521-6942(08)00161-7

doi: 10.1016/j.berh.2008.12.007

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 539-547 , August 2009

Article Tools